|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: FKBP3 |
Gene summary for FKBP3 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | FKBP3 | Gene ID | 2287 |
| Gene name | FKBP prolyl isomerase 3 | |
| Gene Alias | FKBP-25 | |
| Cytomap | 14q21.2 | |
| Gene Type | protein-coding | GO ID | GO:0000413 | UniProtAcc | Q00688 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 2287 | FKBP3 | AEH-subject1 | Human | Endometrium | AEH | 1.26e-19 | -4.08e-01 | -0.3059 |
| 2287 | FKBP3 | AEH-subject2 | Human | Endometrium | AEH | 2.52e-07 | -2.79e-01 | -0.2525 |
| 2287 | FKBP3 | AEH-subject3 | Human | Endometrium | AEH | 2.82e-10 | -2.81e-01 | -0.2576 |
| 2287 | FKBP3 | AEH-subject4 | Human | Endometrium | AEH | 2.20e-07 | -3.20e-01 | -0.2657 |
| 2287 | FKBP3 | AEH-subject5 | Human | Endometrium | AEH | 1.96e-08 | -3.62e-01 | -0.2953 |
| 2287 | FKBP3 | EEC-subject1 | Human | Endometrium | EEC | 8.90e-19 | -3.63e-01 | -0.2682 |
| 2287 | FKBP3 | EEC-subject2 | Human | Endometrium | EEC | 1.00e-15 | -3.81e-01 | -0.2607 |
| 2287 | FKBP3 | EEC-subject3 | Human | Endometrium | EEC | 1.35e-32 | -4.19e-01 | -0.2525 |
| 2287 | FKBP3 | EEC-subject4 | Human | Endometrium | EEC | 1.80e-11 | -3.17e-01 | -0.2571 |
| 2287 | FKBP3 | EEC-subject5 | Human | Endometrium | EEC | 1.28e-03 | -1.92e-01 | -0.249 |
| 2287 | FKBP3 | GSM5276934 | Human | Endometrium | EEC | 2.76e-19 | -4.41e-01 | -0.0913 |
| 2287 | FKBP3 | GSM5276937 | Human | Endometrium | EEC | 5.01e-11 | -4.20e-01 | -0.0897 |
| 2287 | FKBP3 | GSM6177620_NYU_UCEC1_lib1_lib1 | Human | Endometrium | EEC | 1.45e-18 | -2.70e-01 | -0.1869 |
| 2287 | FKBP3 | GSM6177620_NYU_UCEC1_lib2_lib2 | Human | Endometrium | EEC | 9.40e-19 | -2.73e-01 | -0.1875 |
| 2287 | FKBP3 | GSM6177620_NYU_UCEC1_lib3_lib3 | Human | Endometrium | EEC | 2.22e-24 | -2.28e-01 | -0.1883 |
| 2287 | FKBP3 | GSM6177621_NYU_UCEC2_lib1_lib1 | Human | Endometrium | EEC | 2.84e-25 | -1.33e-01 | -0.1934 |
| 2287 | FKBP3 | GSM6177622_NYU_UCEC3_lib1_lib1 | Human | Endometrium | EEC | 2.10e-41 | -1.90e-01 | -0.1917 |
| 2287 | FKBP3 | GSM6177622_NYU_UCEC3_lib2_lib2 | Human | Endometrium | EEC | 5.11e-36 | -2.05e-01 | -0.1916 |
| 2287 | FKBP3 | GSM6177623_NYU_UCEC3_Vis | Human | Endometrium | EEC | 1.69e-02 | -3.10e-02 | -0.1269 |
| 2287 | FKBP3 | LZE2T | Human | Esophagus | ESCC | 1.02e-07 | 1.36e+00 | 0.082 |
| Page: 1 2 3 4 5 6 7 8 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00004133 | Endometrium | AEH | protein peptidyl-prolyl isomerization | 13/2100 | 42/18723 | 4.74e-04 | 4.91e-03 | 13 |
| GO:00182086 | Endometrium | AEH | peptidyl-proline modification | 16/2100 | 58/18723 | 4.75e-04 | 4.91e-03 | 16 |
| GO:000041311 | Endometrium | EEC | protein peptidyl-prolyl isomerization | 14/2168 | 42/18723 | 1.69e-04 | 2.10e-03 | 14 |
| GO:001820813 | Endometrium | EEC | peptidyl-proline modification | 17/2168 | 58/18723 | 2.11e-04 | 2.54e-03 | 17 |
| GO:001820816 | Esophagus | ESCC | peptidyl-proline modification | 46/8552 | 58/18723 | 1.59e-07 | 2.51e-06 | 46 |
| GO:000041313 | Esophagus | ESCC | protein peptidyl-prolyl isomerization | 32/8552 | 42/18723 | 5.52e-05 | 4.27e-04 | 32 |
| GO:00182084 | Liver | Cirrhotic | peptidyl-proline modification | 26/4634 | 58/18723 | 6.65e-04 | 5.04e-03 | 26 |
| GO:00004132 | Liver | Cirrhotic | protein peptidyl-prolyl isomerization | 19/4634 | 42/18723 | 3.00e-03 | 1.71e-02 | 19 |
| GO:001820811 | Liver | HCC | peptidyl-proline modification | 42/7958 | 58/18723 | 3.73e-06 | 4.85e-05 | 42 |
| GO:00004131 | Liver | HCC | protein peptidyl-prolyl isomerization | 31/7958 | 42/18723 | 3.83e-05 | 3.80e-04 | 31 |
| GO:00182088 | Oral cavity | OSCC | peptidyl-proline modification | 42/7305 | 58/18723 | 2.49e-07 | 3.92e-06 | 42 |
| GO:00004134 | Oral cavity | OSCC | protein peptidyl-prolyl isomerization | 28/7305 | 42/18723 | 2.61e-04 | 1.67e-03 | 28 |
| GO:001820815 | Oral cavity | LP | peptidyl-proline modification | 28/4623 | 58/18723 | 8.35e-05 | 1.07e-03 | 28 |
| GO:000041312 | Oral cavity | LP | protein peptidyl-prolyl isomerization | 22/4623 | 42/18723 | 1.04e-04 | 1.26e-03 | 22 |
| GO:00182087 | Prostate | BPH | peptidyl-proline modification | 18/3107 | 58/18723 | 4.75e-03 | 2.27e-02 | 18 |
| GO:001820814 | Prostate | Tumor | peptidyl-proline modification | 18/3246 | 58/18723 | 7.57e-03 | 3.37e-02 | 18 |
| GO:001820810 | Skin | cSCC | peptidyl-proline modification | 37/4864 | 58/18723 | 1.53e-09 | 5.82e-08 | 37 |
| GO:00004136 | Skin | cSCC | protein peptidyl-prolyl isomerization | 26/4864 | 42/18723 | 9.92e-07 | 1.78e-05 | 26 |
| GO:001820817 | Thyroid | PTC | peptidyl-proline modification | 42/5968 | 58/18723 | 2.71e-10 | 8.91e-09 | 42 |
| GO:00004137 | Thyroid | PTC | protein peptidyl-prolyl isomerization | 30/5968 | 42/18723 | 1.65e-07 | 3.13e-06 | 30 |
| Page: 1 2 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| FKBP3 | SNV | Missense_Mutation | c.259A>C | p.Asn87His | p.N87H | Q00688 | protein_coding | deleterious(0.05) | benign(0.078) | TCGA-D8-A1JG-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
| FKBP3 | SNV | Missense_Mutation | c.79N>G | p.Lys27Glu | p.K27E | Q00688 | protein_coding | tolerated(0.26) | benign(0.018) | TCGA-CM-4743-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Chemotherapy | capecitabine | SD | |
| FKBP3 | SNV | Missense_Mutation | c.479N>G | p.Lys160Arg | p.K160R | Q00688 | protein_coding | tolerated(0.14) | benign(0.301) | TCGA-G4-6304-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Chemotherapy | fluorouracil | PD | |
| FKBP3 | SNV | Missense_Mutation | novel | c.341C>A | p.Ser114Tyr | p.S114Y | Q00688 | protein_coding | deleterious(0) | possibly_damaging(0.646) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| FKBP3 | SNV | Missense_Mutation | novel | c.112C>A | p.Leu38Ile | p.L38I | Q00688 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-EI-6917-01 | Colorectum | rectum adenocarcinoma | Male | <65 | III/IV | Chemotherapy | 5fluorouracil+oxaciplatina+l-folinian | SD |
| FKBP3 | SNV | Missense_Mutation | novel | c.644C>A | p.Thr215Asn | p.T215N | Q00688 | protein_coding | deleterious(0.03) | benign(0.001) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| FKBP3 | SNV | Missense_Mutation | rs760527701 | c.211N>T | p.Arg71Cys | p.R71C | Q00688 | protein_coding | deleterious(0.02) | benign(0.007) | TCGA-AX-A2HD-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| FKBP3 | SNV | Missense_Mutation | novel | c.403N>C | p.Tyr135His | p.Y135H | Q00688 | protein_coding | deleterious(0.02) | benign(0.262) | TCGA-B5-A1MR-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| FKBP3 | SNV | Missense_Mutation | c.4N>A | p.Ala2Thr | p.A2T | Q00688 | protein_coding | deleterious_low_confidence(0) | benign(0.053) | TCGA-D1-A176-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| FKBP3 | SNV | Missense_Mutation | novel | c.341N>T | p.Ser114Phe | p.S114F | Q00688 | protein_coding | deleterious(0) | possibly_damaging(0.646) | TCGA-EO-A22X-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unspecific | Carboplatin | Complete Response |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |